67 results about "Growth factor receptor" patented technology

The invention provides a nanogel for rapid permeation of articular cartilage and responsive release of a growth factor, which is prepared by polymerizing a peptide fragment which can be cut by a substance (mainly enzyme) which can be specifically expressed on the surface of osteoarthritis cells or secreted into a matrix with the growth factor, an acrylamide monomer and a cationic micromolecule monomer. Unreacted monomer molecules are filtered out through an ultrafiltration tube or other filtering systems, so that the nanogel which can rapidly permeate into the deep part of articular cartilage and can be recognized and cut by enzyme highly expressed on the surface of osteoarthritis cells or secreted enzyme to release growth factors is prepared, and the effect of the growth factors can be more effectively exerted; the nanogel has strong cartilage infiltration capacity, can completely infiltrate cartilage with the thickness of 1mm within less than 3 days, can be cut by MT1-MMP protein specifically expressed on the surfaces of osteoarthritis cells, releases growth factors, is specifically combined with growth factor receptors on the surfaces of cartilage cells, and activates downstream signal channels, so that the proliferation of the cartilage cells is promoted, and the cartilage cell proliferation rate is increased. The cartilage matrix secretion is promoted, so that the cartilage matrix thickening effect is realized, and the osteoarthritis is prevented and treated.

Systems and methods are disclosed for receiving a target electronic image corresponding to a target specimen, the target specimen comprising a tissue sample of a patient, applying a machine learning system to the target electronic image to identify a region of interest of the target specimen and determine an expression level of, category of, and / or presence of a biomarker in the region of interest, the biomarker comprising at least one from among an epithelial growth factor receptor (EGFR) biomarker and / or a DNA mismatch repair (MMR) deficiency biomarker, the machine learning system having been generated by processing a plurality of training images to predict whether a region of interest is present in the target electronic image, the training images comprising images of human tissue and / or images that are algorithmically generated, and outputting the determined expression level of, category of, and / or presence of the biomarker in the region of interest.

The present invention relates to agents for in vivo imaging and detection of platelet-derived growth factor receptor alpha (PDGFR alpha)-expressing cancers using oxiracemab antibodies and methods of use thereof, including methods for imaging cancer and methods for selecting a patient for treatment.

Substituted pyrrolo[2,3-d]pyrimidines as inhibitors for multi-resistant cancers are described herein. Also provided herein are methods of forming the compounds, methods for inhibiting aurora kinase A and / or aurora kinase B activity and epidermal growth factor activity, methods of treating, ameliorating, or preventing cancer, and uses of the compounds for inhibiting aurora kinase A and / or aurora kinase B activity and epidermal growth factor receptor kinase activity. The compounds are generally of the formulas as illustrated herein, including those of Formula (I-2) or a pharmaceutically acceptable salt thereof:wherein: X1 is N; X2 is N; X3 is —NH—; X4 is N or CR2; X5 is CH, CCH3, or CCOOH; L1 is —NR4—R1; L2 is NH2 or H; R1 is:R2 is H, COOH, a 5-membered heteroaryl, or X6R3; X6R3 is as described herein; R4 is H; R5 is as described herein; and m is 1, 2, 3, 4, or 5.

The present application belongs to the field of biomedical technology, and particularly relates to an axial length and growth trend evaluation method of eye axis based on PDGFRA gene and a PDGFRA enzyme activity control agent. The method comprises the following steps: 1) collecting an eye biological sample of a subject; 2) based on the expression level of PDGFRA gene of platelet-derived growth factor receptor alpha in the collected biological sample; 3) based on the expression level, calculating the axial length of the eye axis according to the quantitative relationship between the expression amount of PDGFRA and the axial length of the eye axis, and predicting the growth trend of the axial length of the eye axis through additional calculation. The technical scheme of the present application can effectively detect and evaluate the axial length of the eye axis, effectively judge the growth trend of the axial length of the eye axis, and directly and efficiently control the axial length of the eye axis and its growth trend through the existing drug components.

The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

The invention discloses application of RMTE in preparation of a medicine for preventing and controlling grass carp reovirus. The hemorrhagic disease caused by the grass carp reovirus (GCRV) is a key bottleneck restricting healthy development of the grass carp breeding industry, and the current vaccine for treating the grass carp reovirus (GCRV) has the problems of unstable immune protection effect, low protection rate for crossing of strains of different genotypes and the like, so that the research and development process of antiviral drugs is slow. The invention discloses an influence and a potential mechanism of a rhodamine B-ethyl sulfide condensation compound (RMTE) on GCRV (Growth Factor Receptor Virus) infection. Results show that the RMTE can significantly inhibit expression of VP6 and VP7 genes in GCRV infected cells, can effectively relieve expression inhibition of GCRV on GPX4, Caspase and p53 genes and promote expression of the three genes, and prove that the RMTE has a significant inhibition effect on GCRV infection and plays an antiviral effect through multiple ways. Research results provide new potential drugs and theoretical basis for prevention and control of GCRV.

A binding domain having a binding specificty to human EGFR (epithelium growth factor receptor) comprises a VH domain and a VL domain, wherein the VH and VL domain each independently comprises a sequence having at least 90% sequence identify to an amino acid sequence as disclosed thereof. The application further provides antibodies comprising the binding domain.

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the adjuvant treatment after tumour resection of patients with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).

The present invention relates to a novel heterocyclic compound which is a compound having FGFR protein activity. Specifically, the invention relates to a compound shown as a formula (II), or pharmaceutically acceptable salt, solvate, polymorphic substance or isomer thereof, and application of the compound in preparation of medicines for treating diseases related to FGFR (Factor Growth Factor Receptor).

Provided herein are methods of engineering a cell line for reduced dependence on exogenous growth factor(s). In some embodiments, the method includes introducing into a cell one or more of: a polynucleotide comprising a coding sequence of a growth factor ligand; a polynucleotide comprising a coding sequence of a growth factor receptor; or a polynucleotide comprising a coding sequence of an activated downstream growth factor target, and culturing the cells in a cultivation infrastructure.

Modified natural killer (NK) cells or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express thrombopoietin receptors, erythropoietin receptors, or chimeric peptides comprising an extracellular domain, a transmembrane domain, and an intracellular domain including an intracellular signaling domain of an interleukin receptor. Methods for treating cancer subjects are also provided, comprising administering modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or an erythropoietin receptor agonist, and in some instances, in combination with interleukin-2, particularly reduced or low doses of IL-2.

The present invention relates to a composition comprising an olaratumab antibody conjugated to a therapeutic radioisotope for the treatment of cancer expressing platelet-derived growth factor receptor alpha (PDGFR-alpha), and to a method of using the same.

The present invention belongs to the technical fields of biomedicine and molecular biology, and particularly relates to a single-chain fragment variable (scFv) targeting human platelet-derived growth factor receptor (PDGFR)-β and use thereof in chimeric antigen receptor (CAR)-T cell immunotherapy. In the present invention, a scFv sequence targeting a human-derived PDGFRβ antigen is first obtained by immunizing a mouse, and then a second-generation CAR is constructed based on this, and additionally a CAR-T cell is obtained via lentivirus infection. The CAR-T cell can effectively kill a PDGFRβ antigen-positive 293T cell. The present invention provides a brand-new idea for eliminating PDGFRβ-positive cells to treat chronic kidney diseases, chronic liver diseases, cardiovascular diseases and various tumor diseases including various organ fibrosis, and has extremely attractive further development value and application prospects.

The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the GRB14 gene, as well as methods of inhibiting expression of GRB14, and methods of treating subjects that would benefit from reduction in expression of GRB14, such as subjects having a GRB14-associated disease, disorder, or condition, such as diabetes, using such dsRNA compositions.

The invention relates to an application of osimertinib combined with chidamide in treatment of osimertinib drug-resistant lung cancer, and particularly relates to the following aspects: (1) osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and shows a remarkable curative effect in treatment of non-small cell lung cancer (NSCLC) patients carrying specific EGFR mutation; (2) chidamide is a novel oral HDACi, can induce cell apoptosis, cell cycle arrest and cell growth inhibition, and shows good tolerance and antitumor activity in various cancer types; and (3) chidamide is taken as an epigenetic regulating agent and can be in synergistic effect with osimertinib, so that the capability of killing lung cancer cells is enhanced. The invention belongs to the technical field of medicines, and particularly provides application of osimertinib combined with chidamide in treatment of osimertinib drug-resistant lung cancer.

The present invention relates to a polynucleotide molecule comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) or fragment thereof, said chimeric antigen receptor (CAR) or fragment thereof i) comprising an extracellular domain comprising an antigen binding region that binds to epidermal growth factor receptor variant III (EGFRvIII); or ii) comprising an extracellular domain comprising an antigen binding region that binds to CD19; wherein the nucleotide sequence encoding the CAR is operably linked to a promoter, and wherein the polynucleotide molecule further comprises a nucleotide sequence encoding a heterologous signal peptide fused to a signal regulatory protein gamma (SIRPy)-related protein (SGRP). The present invention further relates to a chimeric antigen receptor (CAR)-T cell expressing the polynucleotide molecule, as well as a method of treating cancer using said polynucleotide molecule and / or a chimeric antigen receptor (CAR)-T cell expressing said polynucleotide molecule.

Modified platelet-derived growth factor receptor alpha (PDGFRα) polypeptides are described. The modified polypeptides include at least one amino acid substitution that allows the polypeptide to retain the capacity to bind a cytomegalovirus (CMV) trimer comprised of glycoprotein H (gH), gL and gO, but leads to reduced binding to one or more platelet-derived growth factor (PDGF) ligands. Use of the modified PDGFRα polypeptides for inhibiting CMV replication and / or spread, or treating a CMV infection, is also described.

The present invention provides an antitumor agent for treating a patient with a malignant tumor expressing EGFR who has at least one mutation selected from the group consisting of the L718X mutation in exon 18 and the L792X mutation in exon 20, wherein X represents an arbitrary amino acid residue, the antitumor agent comprising (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide (Compound (A)) or a salt thereof.

A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (EGFRt) that lacks the membrane distal EGF-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-EGFR antibody is provided. Cells may be genetically modified to express EGFRt and then purified without the immunoactivity that would accompany the use of full-length EGFR immunoactivity. Through flow cytometric analysis, EGFRt was successfully utilized as an in vivo tracking marker for genetically modified human T cell engraftment in mice. Furthermore, EGFRt was demonstrated to have cellular depletion potential through cetuximab mediated antibody dependent cellular cytotoxicity (ADCC) pathways. Thus, EGFRt may be used as a non-immunogenic selection tool, tracking marker, a depletion tool or a suicide gene for genetically modified cells having therapeutic potential.

The invention relates to an application of an SNP (Single Nucleotide Polymorphism) labeled primer pair in a porcine GFRA1 (Growth Factor Receptor 1) gene coding region in resisting mycoplasma pneumonia traits. The locus of the SNP marker is a molecular marker of the rs329759240 nucleotide locus of a pig GFRA1 gene coding region in a reference sequence of an international pig genome version 11.1, and the SNP marker has A / G polymorphism. According to a primer pair for detecting the SNP marker, an upstream primer is SEQ ID NO: 2, and a downstream primer is SEQ ID NO: 3. The SNP marker provided by the invention can be applied to marker-assisted selection of swine mycoplasmal pneumonia resistant traits, and swine populations or strains resistant to swine mycoplasmal pneumonia traits are screened by identifying the genotype of the SNP marker. Establishment of the group or strain can improve the capability of tolerating swine mycoplasmal pneumonia and produce more social and economic benefits.

The invention discloses an antibody for detecting a soluble platelet-derived growth factor receptor beta, a kit and application. The antibody is prepared by coupling a soluble platelet-derived growth factor receptor beta-specific antigen epitope peptide with a carrier protein and then immunizing an animal, and the amino acid sequence of the soluble platelet-derived growth factor receptor beta-specific antigen epitope peptide is at least one of a sequence shown as SEQ ID NO.1 and a sequence shown as SEQ ID NO.2. The antibody can specifically detect the soluble platelet-derived growth factor receptor beta, and has the advantages of high sensitivity, good specificity, good repeatability and the like; when being used for auxiliary diagnosis or illness monitoring of blood-brain barrier dysfunction related diseases, the kit has good sensitivity, specificity and repeatability, meets clinical application requirements, provides a more accurate and reliable objective index for auxiliary diagnosis, illness monitoring and prognosis evaluation of related diseases, and has important significance and clinical application value.

This disclosure relates to an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) and an anti-EGFR / cMET antibody molecule for use in combination in the treatment of cancer (for example, non-small cell lung cancer [NSCLC]).

Methods of treating a cancer expressing an epidermal growth factor receptor (EGFR) or expressing a hepatocyte growth factor receptor (c-Met) in a subject in need thereof are provided. These methods comprise administering to a subject a therapy comprising an isolated bispecific anti-EGFR / c-Met antibody wherein a dose comprising about 1400 mg to 2100 mg is administered once every 21 day cycle.

The present disclosure provides a pharmaceutical association comprising at least one growth factor receptor-binding compound, which activates at least one growth factor receptor of a neoplastic cell, and at least one adhesion protein inhibitor which inhibits at least one transmembrane cell adhesion protein of said neoplastic cell.

The present invention relates to a compound capable of preventing or treating lung cancer by inhibiting the expression or activity of Anoctamin 1 (ANO1), which is a calcium-activated chloride channel, and epidermal growth factor receptor (EGFR), which is an epithelial growth factor receptor. The compound of the present invention can be advantageously used alone as a composition for preventing or treating lung cancer, can be used per se as a dual-target anticancer drug for ANO1 and EGFR, and can also be used as an adjuvant or a combination preparation in combination with an EGFR-targeted therapeutic agent.

The invention discloses an application of melanine in preparation of an antitumor drug. The invention proposes and verifies that the melanine can significantly inhibit the cell proliferation activity of the epidermal growth factor receptor mutant non-small cell lung cancer by inducing ferroptosis for the first time, and significantly inhibit the migration and diffusion of cancer cells and the colony proliferation and tumorigenesis potential of the cancer cells; and a new choice and direction are provided for clinical treatment of the epidermal growth factor receptor mutant non-small cell lung cancer.

The application discloses a compound with a general formula (I), a pharmaceutically acceptable salt, a hydrate or a prodrug of the compound, and application of the compound in preparation of a medicine for preventing and / or treating diseases mediated by tyrosine kinase and / or histone deacetylase. The compound can simultaneously produce a good inhibiting effect on multiple targets (especially histone deacetylase 1, histone deacetylase 6 and two tyrosine kinases (vascular endothelial cell growth factor receptor and platelet-derived growth factor receptor)), and is expected to be used in treatment of malignant tumors.

The present invention relates to reagents for in vivo imaging and detection of cancer expressing platelet-derived growth factor receptor alpha (PDGFR alpha), as well as methods for imaging cancer and methods for selecting patients for treatment, including methods for using the same.

The invention discloses an application of a near-infrared fluorescent probe in preparation of a near-infrared first region and near-infrared second region diagnosis, prevention and / or treatment medicine, and belongs to the technical field of organic fluorescent molecules. The near-infrared fluorescent probe specifically targets a skin growth factor receptor (EGFR), has good near-infrared first-region and second-region capabilities, can be developed for in vivo diagnosis, can also be used for intraoperative positioning, can be applied to operations such as fluorescent near-infrared first-region and second-region guided tumor and the like, has a certain clinical application prospect, and has a wide application prospect. The method is applied to clinical near-infrared first-zone and second-zone intraoperative navigation.